Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety

@article{Gardin2009CannabinoidRA,
  title={Cannabinoid Receptor Agonist 13, a Novel Cannabinoid Agonist: First in Human Pharmacokinetics and Safety},
  author={Anne Gardin and Klaus Kucher and Beate Kiese and Silke Appel-Dingemanse},
  journal={Drug Metabolism and Disposition},
  year={2009},
  volume={37},
  pages={827 - 833}
}
Cannabinoid receptor agonist 13 (CRA13) is a novel cannabinoid (CB) receptor agonist with high affinity and functional activity toward both CB1 and CB2 receptors. This phase I study aimed to evaluate the pharmacokinetics, safety, and tolerability of single oral doses of CRA13. Sixty-three of 69 healthy adult males were randomized in seven cohorts (n = 9) to receive 1 to 80 mg of CRA13 or placebo orally in fasted condition. To investigate the diet effect, an independent group (n = 6) was… 

Figures and Tables from this paper

Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating &Dgr;9-Tetrahydrocannabinol
TLDR
It is demonstrated that the interoceptive effects of nabilone are similar to &Dgr;9-THC in cannabis users, and the relative success of agonist replacement therapy to manage opioid, tobacco, and stimulant dependence, support the evaluation ofnabilone as a potential medication for cannabis-use disorders.
Synthetic cannabinoids (SC)
Cannabinoid 2 receptor (CB2R) agonists modulate neuropathic pain and cytokine expression
The focus of the work in this dissertation is to elucidate the efficacy of cannabinoid 2 receptor agonists, specifically targeting the spinal cord, for the treatment of chronic neuropathic pain.
Latest advances in cannabinoid receptor agonists
TLDR
Limiting the BBB penetrability, thereby, leading to peripherally restricted CB1/CB2 agonists and enhancing CB2-selectivity emerge as likely prerequisites for avoidance of adverse central CB1 mediated side effects.
Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.
TLDR
An overview of the chemotypes currently under investigation for the development of novel neuropathic pain treatments targeting CB1 receptors is provided.
The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of CNS activity with repeated dosing
TLDR
Significant caution is warranted regarding therapeutic use of CB-13 with the goal of avoiding CNS side effects, but the clear analgesic effect of acute peripheral CB1 receptor activation suggests that peripherally restricted cannabinoids are a viable target for novel analgesic development.
Cannabinoids for the control of experimental multiple sclerosis
TLDR
This study provides further evidence for the efficacy of cannabinoid compounds during an ongoing CNS disease and also their efficacy for treating the consequences of CNS autoimmune disease, which hopefully, will give additional impetus for further clinical investigations of cannabinoid agents in not only multiple sclerosis but also other neurodegenerative diseases of the CNS.
Cannabinoid Receptor 1 Expression in Human Dorsal Root Ganglia and CB13-Induced Bidirectional Modulation of Sensory Neuron Activity
TLDR
It is concluded that peripherally restricted cannabinoids may have both pro- and anti-nociceptive effects in human sensory neurons, and bidirectional modulation of sensory neuron activity suggests that cannabinoids may suppress overall membrane excitability while simultaneously enhancing responsivity to TRPV1-mediated stimuli.
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.
TLDR
In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
TLDR
Cannabinoids are highly potent and efficacious antihyperalgesic agents in a model of neuropathic pain and are likely to be mediated via an action in the CNS and in the periphery.
Food effect on the oral bioavailability of Manidipine: single dose, randomized, crossover study in healthy male subjects
TLDR
The increase in bioavailability of manidipine administered with food is related to its high lipophilicity and may be explained through a solubilization effect produced by food and bile secretions.
Food intake increases the relative oral bioavailability of vanoxerine.
TLDR
It seems likely that food may lower the first-pass metabolism of vanoxerine, as has been shown for other lipophilic basic drugs.
Cannabinoid receptors and their ligands
  • R. Pertwee
  • Biology, Medicine
    European Neuropsychopharmacology
  • 2002
Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial
TLDR
Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.
The effect of food and bile acid administration on the relative bioavailability of cyclosporin.
TLDR
A blood drug concentration vs time curve displaying two peaks was present in 9/11 subjects when cyclosporin was taken with breakfast or with breakfast and bile acid tablets, but only one peak was present when Cyclospor in was taken during fasting, suggesting an enterohepatic circulation of cyclospora or a second absorption phase after the meal.
Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 ‘N of 1’ studies
TLDR
A total of 34 ‘N of 1’ studies were undertaken using this novel therapy for patients with chronic, mainly neuropathic, pain and associated symptoms to explore efficacy, tolerability, safety and dosages of CBME.
...
1
2
3
4
...